No.699
- REGAL trial met its primary endpoint with GPS demonstrating statistically significant and clinically meaningful reduction in risk of death by 41% with median overall survival of 24.0 months versus 14.7 months for best available treatment, and a hazard ratio of 0.59 (p=0.035) -
思っていたよりも、BAT群の成績がよくてびっくりですがHR0.59は普通にすごいですね!!
どこまで織り込まれているかはわからないけど、とりあえず乾杯🍻
返信
投資の参考になりましたか?

